Skip to main content

Idexx Laboratories stock price and financials

  • IDXX · Nasdaq
  • Biotechnology
  • Health Care Equipment
  • S&P 500
$704.23+0.89%Close 13 Nov 2026
Market value
$55.78B
P/E
47.18
EV / EBITDA
33.52
Beta · 1 year
0.82
Return · 1 year
−1.3%
52-week range$500.61 — $769.98

Share price close 16 Nov 2026

+29.3%1 monthHigh $707.41Low $551.21
$550$600$650$700$750Q3 FY2026 report filed 2 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+33.8%6 monthsHigh $707.41Low $504.70
$500$600$700$800Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 2 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+4.6%year to dateHigh $724.76Low $504.70
$500$600$700$800Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 5 May 2026Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 2 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+2.5%1 yearHigh $766.68Low $504.70
$500$600$700$800Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 5 May 2026Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 2 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+53.6%3 yearsHigh $766.68Low $361.04
$200$400$600$800Q4 FY2023 report filed 22 Feb 2024Q1 FY2024 report filed 1 May 2024Q2 FY2024 report filed 6 Aug 2024Q3 FY2024 report filed 31 Oct 2024Q4 FY2024 report filed 21 Feb 2025Q1 FY2025 report filed 1 May 2025Q2 FY2025 report filed 4 Aug 2025Q3 FY2025 report filed 3 Nov 2025Q4 FY2025 report filed 20 Feb 2026Q1 FY2026 report filed 5 May 2026Q2 FY2026 report filed 4 Aug 2026Q3 FY2026 report filed 2 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+509%10 yearsHigh $766.68Low $114.58
$0$200$400$600$800Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Idexx Laboratories reported revenue of $4.30 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 10.4% from fiscal 2024. Net income was $1.06 billion and diluted earnings per share $13.08.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $1.21 billion, up 9.9% from a year earlier.

Figures from Idexx Laboratories's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 2 Nov 2026.

Against Health Care

Growth
Upper half
Revenue +9.7% a year over five years · 15th of 37
Profitability
Top 10%
Return on invested capital 46.9%, five-year average · 1st of 38
Balance sheet
Top quarter
Net debt 0.2× EBITDA · 9th of 38
Valuation
Above the median
P/E 47.2 · 27th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$4.30B+10.4%
Net income
$1.06B+19.3%
Diluted EPS
$13.08+22.6%
Gross margin
61.8%+0.8 pts
Free cash flow
$1.06B+30.8%
Net debt
$398.0M−11.3%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$1B$2B$3B$4B$5BRevenue, FY16: $1.78BNet income, FY16: $222.04MFY16Revenue, FY17: $1.97BNet income, FY17: $263.14MFY17Revenue, FY18: $2.21BNet income, FY18: $377.03MFY18Revenue, FY19: $2.41BNet income, FY19: $427.72MFY19Revenue, FY20: $2.71BNet income, FY20: $581.78MFY20Revenue, FY21: $3.22BNet income, FY21: $744.85MFY21Revenue, FY22: $3.37BNet income, FY22: $679.09MFY22Revenue, FY23: $3.66BNet income, FY23: $845.04MFY23Revenue, FY24: $3.9BNet income, FY24: $887.87MFY24Revenue, FY25: $4.3BNet income, FY25: $1.06BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 2 Nov 2026 · Full results →

Revenue
$1.21B+9.9% on a year
Gross margin
62.9%+1.1 pts on a year
Operating income
$402.3M+13.4% on a year
Net income
$317.1M+15.5% on a year
Diluted EPS
$4.01+17.9% on a year
Free cash flow
$420.8M+13.4% on a year

Comparable companies All of Health Care →

Idexx Laboratories beside the other S&P 500 members in Health Care Equipment, by market value.

Idexx Laboratories and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
GE HealthCareGEHC$37.71B+1.4%+10.7%+6.9%10.0%17.5

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%25%50%75%61.8%31.6%24.6%FY16FY19FY22FY25

Idexx Laboratories revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Idexx Laboratories revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
CAG$2.89B$3.06B+5.8%$3.35B+9.6%$3.57B+6.6%$3.95B+10.6%
Water segment revenue$146.5M$155.7M+6.3%$168.1M+8.0%$185.1M+10.1%$201.1M+8.7%
LPD$135.9M$122.6M−9.8%$121.7M−0.8%$122.1M+0.3%$131.8M+8.0%
Other revenue$43.01M$30.20M−29.8%$18.79M−37.8%$16.29M−13.3%$17.48M+7.3%
Total revenue$3.22B$3.37B$3.66B$3.90B$4.30B

By product

Idexx Laboratories revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Product revenue$1.88B$1.93B+2.9%$2.09B+8.4%$2.25B+7.6%$2.54B+12.9%
Service revenue$1.34B$1.44B+7.4%$1.57B+9.2%$1.65B+5.0%$1.76B+7.0%
Total revenue$3.22B$3.37B$3.66B$3.90B$4.30B

By region

Idexx Laboratories revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$2.00B$2.18B+9.4%$2.39B+9.5%$2.53B+5.9%$2.75B+8.7%
Asia Pacific$331.4M$319.6M−3.6%$319.3M−0.1%$321.0M+0.5%$355.9M+10.9%
Other———$196.3M$230.0M+17.2%
Canada$139.7M$142.7M+2.2%$150.1M+5.2%$152.9M+1.8%$167.3M+9.4%
United Kingdom$115.0M$110.4M−4.0%$121.7M+10.3%$134.6M+10.6%$154.4M+14.7%
FR$90.84M$84.48M−7.0%$96.80M+14.6%$110.8M+14.5%$126.0M+13.7%
AU$94.41M$96.41M+2.1%$95.47M−1.0%$102.0M+6.8%$112.2M+10.1%
Latin America & Caribbean$66.62M$75.03M+12.6%$83.92M+11.8%$83.69M−0.3%$90.41M+8.0%
Japan$84.28M$77.66M−7.8%$75.57M−2.7%$73.14M−3.2%$83.36M+14.0%
ES$48.17M$46.98M−2.5%$52.33M+11.4%$61.86M+18.2%$70.97M+14.7%
IT$52.06M$48.19M−7.4%$53.79M+11.6%$58.22M+8.2%$66.86M+14.8%
CH——$34.83M$37.18M+6.8%$41.70M+12.1%
NL———$34.05M$40.50M+19.0%
Total revenue$3.22B$3.37B$3.66B$3.90B$4.30B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Idexx Laboratories income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$1.78B$1.97B$2.21B$2.41B$2.71B$3.22B$3.37B$3.66B$3.90B$4.30B
Revenue growth+10.8%+10.9%+12.4%+8.8%+12.5%+18.8%+4.7%+8.7%+6.5%+10.4%
Gross profit$975.4M$1.10B$1.24B$1.37B$1.57B$1.89B$2.00B$2.19B$2.38B$2.66B
Operating income$350.2M$413.0M$491.3M$552.8M$694.5M$932.0M$898.8M$1.10B$1.13B$1.36B
Net income$222.0M$263.1M$377.0M$427.7M$581.8M$744.8M$679.1M$845.0M$887.9M$1.06B
Diluted EPS$2.44$2.94$4.26$4.89$6.71$8.60$8.03$10.06$10.67$13.08
Gross margin54.9%55.7%56.1%56.7%58.0%58.8%59.5%59.8%61.0%61.8%
Operating margin19.7%21.0%22.2%23.0%25.7%29.0%26.7%30.0%29.0%31.6%
Net margin12.5%13.4%17.0%17.8%21.5%23.2%20.2%23.1%22.8%24.6%

Cash flow

Idexx Laboratories cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$338.9M$373.3M$400.1M$459.2M$648.1M$755.5M$543.0M$906.5M$929.0M$1.18B
Capital expenditure$64.79M$74.38M$115.8M$155.0M$107.0M$119.5M$148.8M$133.6M$120.9M$124.7M
Free cash flow$274.2M$298.9M$284.3M$304.2M$541.1M$636.0M$394.1M$772.9M$808.1M$1.06B

Balance sheet and shares

Idexx Laboratories balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$154.9M$187.7M$123.8M$90.33M$383.9M$144.5M$112.5M$453.9M$288.3M$180.1M
Total debt$593.7M$606.6M$601.8M$781.7M$1.00B$957.5M$891.0M$817.4M$736.9M$578.1M
Shareholders' equity−$108.4M−$54.11M−$9.51M$177.5M$632.1M$690.0M$608.7M$1.48B$1.60B$1.61B
Diluted shares90.9M89.6M88.5M87.5M86.7M86.6M84.6M84.0M83.2M81.0M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Idexx Laboratories quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$954.3M$998.4M$1.11B$1.11B$1.09B$1.14B$1.22B$1.21B
Revenue, year on year+5.8%+3.6%+10.6%+13.3%+14.3%+14.3%+9.7%+9.9%
Gross margin59.8%62.4%62.6%61.8%60.3%63.4%64.0%62.9%
Operating income$261.7M$316.5M$373.0M$354.8M$315.6M$362.6M$425.6M$402.3M
Net income$216.1M$242.7M$294.0M$274.6M$248.2M$278.4M$338.4M$317.1M
Diluted EPS$2.62$2.96$3.63$3.40$3.08$3.47$4.27$4.01
Free cash flow$232.8M$207.9M$151.6M$371.2M$326.3M$234.3M$322.5M$420.8M

Operating KPIs

The operating figures Idexx Laboratories reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Idexx Laboratories operating KPIs
KPILatestPeriodChange on a yearRecent periods
CAG diagnostics recurring revenue (Organic growth · Updated · change on a year)9.5%quarter to 30 Jun 2026up 3.7 points
Product revenue$722.9Mquarter to 30 Sep 2026up 10.2%
Service revenue$491.4Mquarter to 30 Sep 2026up 9.4%
IDEXX VetLab consumables revenue$443.2Mquarter to 30 Sep 2026up 14.3%
Reference laboratory diagnostic and consulting services revenue$399.1Mquarter to 30 Sep 2026up 10.0%
Rapid assay products revenue$89.1Mquarter to 30 Sep 2026up 0.6%
Recurring revenue$77.5Mquarter to 30 Sep 2026up 9.1%
CAG Diagnostics capital - instruments revenue$51.5Mquarter to 30 Sep 2026unchanged
CAG Diagnostics services and accessories revenue$35.9Mquarter to 30 Sep 2026up 5.3%
Systems and hardware revenue$19.7Mquarter to 30 Sep 2026up 17.0%
CAG revenue$1.1Bquarter to 30 Sep 2026up 10.2%
Water segment revenue$58.8Mquarter to 30 Sep 2026up 8.4%
LPD revenue$34.8Mquarter to 30 Sep 2026up 2.6%
Americas revenue$3.0Bfiscal year to 31 Dec 2025up 8.7%
United States revenue$766.6Mquarter to 30 Sep 2026up 8.7%
Europe, the Middle East and Africa revenue$267.1Mquarter to 30 Sep 2026up 9.0%
Germany revenue$206.8Mfiscal year to 31 Dec 2025up 19.0%
United Kingdom revenue$154.4Mfiscal year to 31 Dec 2025up 14.7%
FR revenue$126.0Mfiscal year to 31 Dec 2025up 13.7%
AU revenue$112.2Mfiscal year to 31 Dec 2025up 10.1%
Asia Pacific revenue$104.9Mquarter to 30 Sep 2026up 15.6%
Japan revenue$83.4Mfiscal year to 31 Dec 2025up 14.0%
ES revenue$71.0Mfiscal year to 31 Dec 2025up 14.7%
IT revenue$66.9Mfiscal year to 31 Dec 2025up 14.8%
Canada revenue$49.0Mquarter to 30 Sep 2026up 18.5%
CH revenue$41.7Mfiscal year to 31 Dec 2025up 12.1%
NL revenue$40.5Mfiscal year to 31 Dec 2025up 19.0%
China revenue$36.0Mfiscal year to 31 Dec 2025up 0.4%
Latin America & Caribbean revenue$26.6Mquarter to 30 Sep 2026up 15.4%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Idexx Laboratories's revenue in fiscal 2025?

$4.30 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Idexx Laboratories's net income in fiscal 2025?

$1.06 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Idexx Laboratories's diluted earnings per share in fiscal 2025?

$13.08 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Idexx Laboratories's gross margin?

61.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Idexx Laboratories's operating margin?

31.6% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Idexx Laboratories generate in fiscal 2025?

$1.06 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Idexx Laboratories's revenue come from?

In fiscal 2025, by segment: CAG $3.95B (92%), Water segment revenue $201.1M (4.7%), LPD $131.8M (3.1%), Other revenue $17.48M (0.4%), out of $4.30B in all, as stated in its annual report.

In the terminal

Twenty years of Idexx Laboratories's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans